FRI0191 Biosimilar Candidate ABP 501: Additional Efficacy Analyses from The Phase 3 Study

Authors
Category Primary study
Year 2016
This article has no abstract
Epistemonikos ID: c530519d3b1aa737242b5ffcb767a278b39a8a19
First added on: Nov 07, 2017